These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26480664)

  • 1. [Effects of GLP-1 Agonist Exenatide on Cardiac Diastolic Function and Vascular Endothelial Function in Diabetic Patients].
    Wang XH; Han LN; Yu YR; Wang C; Wang B; Wen XR; Huang H; Jing XC
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Jul; 46(4):586-90. PubMed ID: 26480664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH
    Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes.
    Scalzo RL; Moreau KL; Ozemek C; Herlache L; McMillin S; Gilligan S; Huebschmann AG; Bauer TA; Dorosz J; Reusch JE; Regensteiner JG
    J Diabetes Complications; 2017 Feb; 31(2):449-455. PubMed ID: 27884660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial.
    Shi L; Zhu J; Yang P; Tang X; Yu W; Pan C; Shen M; Zhu D; Cheng J; Ye X
    Obes Res Clin Pract; 2017; 11(5):607-615. PubMed ID: 28161303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
    Diamant M; Van Gaal L; Guerci B; Stranks S; Han J; Malloy J; Boardman MK; Trautmann ME
    Lancet Diabetes Endocrinol; 2014 Jun; 2(6):464-73. PubMed ID: 24731672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study of concomitant GLP-1 analogue and insulin use in type 2 diabetes in clinical practice.
    van Velsen EF; Lamers J; Blok V; van Leendert RJ; Kiewiet-Kemper RM
    Neth J Med; 2014 Dec; 72(10):523-7. PubMed ID: 26219757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.
    Iltz JL; Baker DE; Setter SM; Keith Campbell R
    Clin Ther; 2006 May; 28(5):652-65. PubMed ID: 16861088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
    Thompson AM; Trujillo JM
    Ann Pharmacother; 2015 Mar; 49(3):351-9. PubMed ID: 25565404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Serné EH; van Raalte DH
    Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2125-32. PubMed ID: 27562916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers.
    Gurkan E; Tarkun I; Sahin T; Cetinarslan B; Canturk Z
    Diabetes Res Clin Pract; 2014 Dec; 106(3):567-75. PubMed ID: 25458329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HOMA-S is associated with greater HbA1c reduction with a GLP-1 analogue in patients with type 2 diabetes.
    Heald AH; Narayanan RP; Lowes D; Jarman E; Onyekwelu E; Qureshi Z; Laing I; Anderson SG
    Exp Clin Endocrinol Diabetes; 2012 Jul; 120(7):420-3. PubMed ID: 22639398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
    Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
    Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.
    Montvida O; Klein K; Kumar S; Khunti K; Paul SK
    Diabetes Obes Metab; 2017 Jan; 19(1):108-117. PubMed ID: 27629433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
    Malloy J; Meloni A; Han J
    Postgrad Med; 2013 May; 125(3):58-67. PubMed ID: 23748507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy.
    Karagianni P; Polyzos SA; Kartali N; Zografou I; Sambanis C
    Adv Med Sci; 2013; 58(1):38-43. PubMed ID: 23640946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review.
    Albèr A; Brønden A; Knop FK
    Diabetes Obes Metab; 2017 Jul; 19(7):915-925. PubMed ID: 28211611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.